Brief: Palvella Completes Phase 2 TOIVA Trial Enrollment for QTORIN Rapamycin in Treating Cutaneous Venous Malformations
15/09/2025 12:34
Sept 15 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TOIVA TRIAL OF QTORIN™ RAPAMYCIN FOR CUTANEOUS VENOUS MALFORMATIONS PALVELLA THERAPEUTICS INC - TOP-LINE RESULTS FROM TOIVA EXPECTED MID-DECEMBER 2025 Source text: ID:nGNX7T470Q Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs